BR112015022623A2 - composição e métodos baseados em anticorpos neutralizantes, administrados por via intranasal para eficácia terapêutica melhorada - Google Patents

composição e métodos baseados em anticorpos neutralizantes, administrados por via intranasal para eficácia terapêutica melhorada

Info

Publication number
BR112015022623A2
BR112015022623A2 BR112015022623A BR112015022623A BR112015022623A2 BR 112015022623 A2 BR112015022623 A2 BR 112015022623A2 BR 112015022623 A BR112015022623 A BR 112015022623A BR 112015022623 A BR112015022623 A BR 112015022623A BR 112015022623 A2 BR112015022623 A2 BR 112015022623A2
Authority
BR
Brazil
Prior art keywords
therapeutic efficacy
improved therapeutic
administered intranasally
administration
methods
Prior art date
Application number
BR112015022623A
Other languages
English (en)
Inventor
Vigil Adam
Wittekind Michael
Original Assignee
Contrafect Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Contrafect Corp filed Critical Contrafect Corp
Publication of BR112015022623A2 publication Critical patent/BR112015022623A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1018—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/544—Mucosal route to the airways
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Otolaryngology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

resumo da patente de invenã§ã£o para: ”composiã‡ãƒo e mã‰todos baseados em anticorpos neutralizantes, administrados por via intranasal para eficãcia terapãšutica melhorada. a presente invenã§ã£o proporciona mã©todos para o tratamento ou profilaxia de vã­rus, particularmente vã­rus de influenza, atravã©s da administraã§ã£o de agentes, particularmente anticorpos neutralizantes ou fragmentos ativos dos mesmos, diretamente no trato respiratã³rio, incluindo atravã©s da administraã§ã£o intranasal ou por inalaã§ã£o. a invenã§ã£o proporciona composiã§ãµes adequadas para o tratamento e administraã§ã£o intranasal ou por inalaã§ã£o. a invenã§ã£o inclui mã©todos para o tratamento ou profilaxia combinando a administraã§ã£o intranasal ou por inalaã§ã£o com a administraã§ã£o de anticorpos intraperitoneal ou intravenosa.
BR112015022623A 2013-03-14 2014-03-14 composição e métodos baseados em anticorpos neutralizantes, administrados por via intranasal para eficácia terapêutica melhorada BR112015022623A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361782661P 2013-03-14 2013-03-14
PCT/US2014/027939 WO2014152841A1 (en) 2013-03-14 2014-03-14 Composition and methods based on neutralizing antibodies delivered intranasally for enhanced therapeutic efficacy

Publications (1)

Publication Number Publication Date
BR112015022623A2 true BR112015022623A2 (pt) 2017-07-18

Family

ID=51581334

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015022623A BR112015022623A2 (pt) 2013-03-14 2014-03-14 composição e métodos baseados em anticorpos neutralizantes, administrados por via intranasal para eficácia terapêutica melhorada

Country Status (14)

Country Link
US (3) US11827693B2 (pt)
EP (1) EP3003373A4 (pt)
JP (1) JP6595448B2 (pt)
KR (1) KR20150138236A (pt)
CN (1) CN105209071A (pt)
AU (2) AU2014236508A1 (pt)
BR (1) BR112015022623A2 (pt)
CA (1) CA2906676A1 (pt)
HK (1) HK1223301A1 (pt)
IL (1) IL241552B2 (pt)
MX (1) MX2015012397A (pt)
RU (1) RU2701694C2 (pt)
WO (1) WO2014152841A1 (pt)
ZA (1) ZA201507577B (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2787099A1 (en) 2009-03-30 2010-10-14 Anice C. Lowen Influenza virus hemagglutinin polypeptides containing stem domains, vaccines and uses thereof
CA2792537A1 (en) 2010-03-30 2011-10-06 Mount Sinai School Of Medicine Influenza virus vaccines and uses thereof
EP2758075B1 (en) 2011-09-20 2023-05-03 Icahn School of Medicine at Mount Sinai Influenza virus vaccines and uses thereof
CA2861515A1 (en) 2011-12-05 2013-06-13 Trellis Bioscience, Llc Antibodies useful in passive influenza immunization
NZ627796A (en) 2012-12-18 2017-07-28 Icahn School Med Mount Sinai Influenza virus vaccines and uses thereof
AU2014236508A1 (en) 2013-03-14 2015-09-17 Contrafect Corporation Composition and methods based on neutralizing antibodies delivered intranasally for enhanced therapeutic efficacy
WO2014159960A1 (en) 2013-03-14 2014-10-02 Icahn School Of Medicine At Mount Sinai Antibodies against influenza virus hemagglutinin and uses thereof
US10639370B2 (en) 2014-02-04 2020-05-05 Contrafect Corporation Antibodies useful in passive influenza immunization, and compositions, combinations and methods for use thereof
EP3102598A2 (en) 2014-02-04 2016-12-14 Contrafect Corporation Antibodies useful in passive influenza immunization, and compositions, combinations and methods for use thereof
US10005833B2 (en) * 2015-01-02 2018-06-26 Washington State University Methods of treating inflammation associated airway diseases and viral infections
JP2018504412A (ja) 2015-01-23 2018-02-15 アイカーン スクール オブ メディシン アット マウント サイナイ インフルエンザウイルスワクチン接種レジメン
WO2016200543A2 (en) 2015-05-13 2016-12-15 The Trustees Of The University Of Pennsylvania Aav-mediated expression of anti-inluenza antibodies and methods of use thereof
US11266734B2 (en) 2016-06-15 2022-03-08 Icahn School Of Medicine At Mount Sinai Influenza virus hemagglutinin proteins and uses thereof
WO2018187706A2 (en) 2017-04-07 2018-10-11 Icahn School Of Medicine At Mount Sinai Anti-influenza b virus neuraminidase antibodies and uses thereof
JPWO2021002355A1 (pt) 2019-07-03 2021-01-07
WO2021011404A1 (en) * 2019-07-12 2021-01-21 Contrafect Corporation Therapeutic protein formulations comprising antibodies and uses thereof

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4625015A (en) 1982-08-23 1986-11-25 Scripps Clinic & Research Foundation Broad spectrum influenza antisera
JPS62175426A (ja) 1986-01-27 1987-08-01 Kazufumi Shimizu 抗体及びこれを有効成分とするスプレ−剤
US6235708B1 (en) 1998-11-20 2001-05-22 Zymogenetics, Inc Testis-specific cystatin-like protein cystatin T
US20020006656A1 (en) 1999-12-23 2002-01-17 Holloway James L. Zcys5: a member of the cystatin superfamily
FR2817869B1 (fr) 2000-12-07 2005-01-14 Technopharm Anticorps monoclonal humain dirige contre le virus influenza ou un fragment de celui-ci
WO2002081655A2 (en) 2001-03-28 2002-10-17 Children's Medical Center Corporation Fusion protein construct and method for inducing hiv-specific serum igg and secretory iga antibodies in-vivo
WO2003080672A1 (en) 2002-03-22 2003-10-02 Aprogen, Inc. Humanized antibody and process for preparing same
EP1603590A4 (en) 2003-03-07 2008-08-27 Merck & Co Inc INFLUENZA VIRUS VACCINE
KR101206206B1 (ko) 2003-07-22 2012-11-29 크루셀 홀란드 비.브이. 사스-코로나바이러스에 대한 결합분자 및 그것의 용도
EP2024393A2 (en) 2006-05-15 2009-02-18 Sea Lane Biotechnologies,llc. Neutralizing antibodies to influenza viruses
EP2078732B1 (en) 2006-07-10 2015-09-16 Fujita Health University Method of identifying a candidate diagnostic or therapeutic antibody using flow cytometry
MY170607A (en) * 2006-09-07 2019-08-20 Crucell Holland Bv Human binding molecules capable of neutralizing influenza virus h5n1 and uses thereof
WO2008110937A2 (en) * 2007-03-13 2008-09-18 Humabs Llc Antibodies against h5n1 strains of influenza a virus
MX2009013008A (es) * 2007-05-31 2010-06-09 Vacunas para la influenza.
FR2921928B1 (fr) 2007-10-08 2011-03-04 Sanofi Pasteur Anticorps monoclonaux specifiques de l'hemagglutinine du virus grippal
EP2222701B1 (en) * 2007-12-06 2017-11-01 Dana-Farber Cancer Institute, Inc. Antibodies against influenza virus and methods of use thereof
AU2009221915A1 (en) 2008-03-03 2009-09-11 Dyax Corp. Metalloproteinase 12 binding proteins
WO2009121004A2 (en) 2008-03-28 2009-10-01 Sea Lane Biotechnologies, Llc Neutralizing molecules to viral antigens
JP2011528902A (ja) 2008-07-25 2011-12-01 インスティテュート・フォー・リサーチ・イン・バイオメディシン 抗ａ型インフルエンザウイルス中和抗体およびその使用
CL2009001735A1 (es) 2008-08-19 2010-02-19 Regeneron Pharma Anticuerpo humano o fragmento de union a antigeno del mismo que une e inhibe actividad de ligando del activador del receptor de nf-kb (rankl); adn codificante; vector de expresion; metodo para producir dicho anticuerpo; composicion farmaceutica que lo comprende; uso para atenuar o inhibir enfermedad o condicion mediada por rankl
EP2328928A2 (en) 2008-08-25 2011-06-08 Dana-Farber Cancer Institute, Inc. Conserved influenza hemagglutinin epitope and antibodies thereto
AU2008365616A1 (en) 2008-12-24 2011-08-11 Temasek Life Sciences Laboratory Limited Monoclonal antibodies specific to the fusion peptide from hemagglutinin from influenza A viruses and uses thereof
CN102264896B (zh) * 2008-12-25 2014-02-26 国立大学法人大阪大学 抗人流感病毒人型抗体
BRPI1012749B1 (pt) 2009-05-11 2022-01-11 Janssen Vaccines & Prevention B.V. Anticorpo monoclonal humano, seu uso e seu método de produção, imunoconjugado, e composição farmacêutica
AU2010249046A1 (en) * 2009-05-13 2011-12-01 Sea Lane Biotechnologies, Llc Neutralizing molecules to influenza viruses
JP5941841B2 (ja) 2009-05-26 2016-06-29 アイカーン スクール オブ メディシン アット マウント サイナイ 周期的投与によって作製されたインフルエンザウイルスに対するモノクローナル抗体及びその使用
EA029198B1 (ru) 2010-03-26 2018-02-28 Помона Ричерка С.Р.Л. Полноразмерные иммуноглобулины изотипа igg, способные к распознаванию нейтрализующего эпитопа в области стебля гемагглютинина различных подтипов и их использование в качестве лекарственного средства против гриппа
HUE030724T2 (en) 2010-04-09 2017-06-28 Univ Utrecht Holding Bv Recombinant multimer influenza proteins
WO2011160083A1 (en) 2010-06-17 2011-12-22 Trellis Bioscience, Inc. Antibodies useful in passive influenza immuization
JP2013540701A (ja) 2010-08-12 2013-11-07 セラクローン サイエンシーズ， インコーポレイテッド 抗赤血球凝集素抗体組成物およびその使用方法
US20130289246A1 (en) 2010-09-30 2013-10-31 Vanderbilt University Influenza virus antibodies and immunogens and uses therefor
MX346206B (es) * 2011-07-14 2017-03-09 Crucell Holland Bv Moleculas de enlace humanas capaces de neutralizar los virus de la influenza a del grupo filogenetico 1 y grupo filogenetico 2 y virus de la influenza b.
CA2861515A1 (en) 2011-12-05 2013-06-13 Trellis Bioscience, Llc Antibodies useful in passive influenza immunization
JP6170507B2 (ja) * 2012-01-31 2017-07-26 国立大学法人大阪大学 Ｂ型インフルエンザウイルスに対する広範な保護を与えるヒトモノクローナル抗体及びその使用方法
WO2013132007A1 (en) 2012-03-08 2013-09-12 Crucell Holland B.V. Human binding molecules capable of binding to and neutralizing influenza b viruses and uses thereof
US9969794B2 (en) 2012-05-10 2018-05-15 Visterra, Inc. HA binding agents
AU2014236508A1 (en) * 2013-03-14 2015-09-17 Contrafect Corporation Composition and methods based on neutralizing antibodies delivered intranasally for enhanced therapeutic efficacy
EP3610203A4 (en) 2017-04-14 2021-01-06 Johnson Controls Technology Company MULTIFUNCTIONAL THERMOSTAT WITH INTELLIGENT FAN CONTROL FOR FREEZE / MOLD PROTECTION AND AIR QUALITY CONTROL

Also Published As

Publication number Publication date
US20170334974A1 (en) 2017-11-23
AU2019200045A1 (en) 2019-01-31
JP6595448B2 (ja) 2019-10-23
WO2014152841A1 (en) 2014-09-25
MX2015012397A (es) 2016-07-26
IL241552B2 (en) 2023-09-01
US20160083456A1 (en) 2016-03-24
KR20150138236A (ko) 2015-12-09
HK1223301A1 (zh) 2017-07-28
AU2014236508A1 (en) 2015-09-17
RU2701694C2 (ru) 2019-09-30
IL241552B1 (en) 2023-05-01
US11827693B2 (en) 2023-11-28
ZA201507577B (en) 2018-05-30
AU2019200045B2 (en) 2020-11-26
CN105209071A (zh) 2015-12-30
JP2016519074A (ja) 2016-06-30
US9718875B2 (en) 2017-08-01
US20170002062A1 (en) 2017-01-05
IL241552A (pt) 2015-11-30
EP3003373A1 (en) 2016-04-13
RU2015136392A (ru) 2017-04-19
CA2906676A1 (en) 2014-09-25
EP3003373A4 (en) 2016-10-19

Similar Documents

Publication Publication Date Title
BR112015022623A2 (pt) composição e métodos baseados em anticorpos neutralizantes, administrados por via intranasal para eficácia terapêutica melhorada
BR112015019720A2 (pt) inibidores de (benzil-ciano-metil)-amidas de ácido 2-aza-biciclo[2.2.1]heptano-3-carboxílico substituído da catepsina c
BR112012001297A2 (pt) conector.
BR112013029537A2 (pt) derivados de quinazolina para tratamento de infecções virais e outras doenças
EA201490809A1 (ru) Способы и композиции для лечения неэффективного эритропоэза
BR112015027282A2 (pt) fenfluramina para uso no tratamento de síndrome de dravet
EA201791916A1 (ru) 2'-замещенные карбануклеозидные аналоги для противовирусного лечения
BR112015001419A2 (pt) composto, composição farmacêutica, e, métodos para inibir romk em um paciente, para causar diurese, natriurese ou ambos e para tratamento de um ou mais distúrbios
BR112015029512A2 (pt) derivados de pirazolopirrolidina e seu uso no tratamento de doenças
BR112015007366A2 (pt) derivados de acilaminopirimidina para o tratamento de infecções virais e outras doenças
BR112015022197A8 (pt) uso de um composto para fabricação de um medicamento ou composição farmacêutica para o tratamento de cataplexia
BR112014024159A2 (pt) Formulações de vacina oral específicas do local gastrintestinal , ativas no íleo e apêndice.
BR112015010396A2 (pt) terapia de combinação
BR112015013695A2 (pt) composição farmacêutica, e, métodos para tratamento e para prevenção de uma infecção por hiv
MX2014002171A (es) Tratamientos de combinacion para hepatitis c.
UY34359A (es) ?tratamiento de esclerosis múltiple con combinación de laquinimod e interferón-beta?.
EA201490377A1 (ru) Лечение рассеянного склероза комбинацией лаквинимода и глатирамера ацетата
EA201590933A1 (ru) Новые перорально биодоступные соединения, модулирующие контроль дыхания, и способы их использования
BR112014008036A2 (pt) tratamento de rinite
TN2014000345A1 (en) Pharmaceutical preparation containing an antivirally active dihydroquinazoline derivative
CY1118399T1 (el) Ενωσεις βενζοφουρανιου για την θεραπεια μολυνσεων ιου ηπατιτιδας c
BR112015017775A2 (pt) enzima cistationina beta-sintase para o tratamento de homocistinúria
BR112014030813A2 (pt) tratamento de efeitos colaterais de desordens motoras e de movimento associadas com tratamentos de doenças parkinson
BR112014019399A2 (pt) métodos de tratamento da fibrose
BR112014002674A2 (pt) 3-(bifenil-3-il)-4-hidróxi-8-metóxi-1-azaspiro[4.5]dec-3-en-2-onas substituídas

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]